Ovarian cancer screening: Difference between revisions
Jump to navigation
Jump to search
Hudakarman (talk | contribs) No edit summary |
Hudakarman (talk | contribs) No edit summary |
||
| Line 8: | Line 8: | ||
*Ovarian cancer the fifth most common cause of cancer-related mortality in women | *Ovarian cancer the fifth most common cause of cancer-related mortality in women | ||
*75% of women with ovarian cancer are diagnosed in an advanced stage | *75% of women with ovarian cancer are diagnosed in an advanced stage | ||
*Ovarian cancer is the most lethal gynecological cancer<ref name="pmid28170086">{{cite journal| author=Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D et al.| title=Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening. | journal=CA Cancer J Clin | year= 2017 | volume= 67 | issue= 2 | pages= 100-121 | pmid=28170086 | doi=10.3322/caac.21392 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28170086 }} </ref> | |||
*The reason of increased mortality and late detection of ovarian cancer in its advanced stage is because the screening systems that are being used don't have the required sensitivity and specificity<ref name="pmid27284942">{{cite journal| author=Galea M, Gauci G, Calleja-Agius J, Schembri-Wismayer P| title=Peritoneal biomarkers in the early detection of ovarian cancer. | journal=Minerva Ginecol | year= 2017 | volume= 69 | issue= 1 | pages= 84-99 | pmid=27284942 | doi=10.23736/S0026-4784.16.03943-5 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27284942 }} </ref>. | *The reason of increased mortality and late detection of ovarian cancer in its advanced stage is because the screening systems that are being used don't have the required sensitivity and specificity<ref name="pmid27284942">{{cite journal| author=Galea M, Gauci G, Calleja-Agius J, Schembri-Wismayer P| title=Peritoneal biomarkers in the early detection of ovarian cancer. | journal=Minerva Ginecol | year= 2017 | volume= 69 | issue= 1 | pages= 84-99 | pmid=27284942 | doi=10.23736/S0026-4784.16.03943-5 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27284942 }} </ref>. | ||
*Biomarkers from peritoneal fluid can be used as a mean of ealy detection of ovarian cancer but this is stil an emerging proof. | *Biomarkers from peritoneal fluid can be used as a mean of ealy detection of ovarian cancer but this is stil an emerging proof. | ||
Revision as of 15:48, 12 July 2019
|
Ovarian cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Ovarian cancer screening On the Web |
|
American Roentgen Ray Society Images of Ovarian cancer screening |
|
Risk calculators and risk factors for Ovarian cancer screening |
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
- There are no recommendations for screening ovarian cancer in asymptomatic women although better outcome is associated with early diagnosis[1]
- Ovarian cancer the fifth most common cause of cancer-related mortality in women
- 75% of women with ovarian cancer are diagnosed in an advanced stage
- Ovarian cancer is the most lethal gynecological cancer[2]
- The reason of increased mortality and late detection of ovarian cancer in its advanced stage is because the screening systems that are being used don't have the required sensitivity and specificity[1].
- Biomarkers from peritoneal fluid can be used as a mean of ealy detection of ovarian cancer but this is stil an emerging proof.
References
- ↑ 1.0 1.1 Galea M, Gauci G, Calleja-Agius J, Schembri-Wismayer P (2017). "Peritoneal biomarkers in the early detection of ovarian cancer". Minerva Ginecol. 69 (1): 84–99. doi:10.23736/S0026-4784.16.03943-5. PMID 27284942.
- ↑ Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D; et al. (2017). "Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening". CA Cancer J Clin. 67 (2): 100–121. doi:10.3322/caac.21392. PMID 28170086.